AdventHealth Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, FL, 32804, USA; Beaumont Gynecologic Oncology Associates, Beaumont Hospital-Dearborn, Dearborn, MI, 48124, USA.
AdventHealth Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, FL, 32804, USA.
Gynecol Oncol. 2019 Dec;155(3):468-472. doi: 10.1016/j.ygyno.2019.09.019. Epub 2019 Oct 7.
To determine which non-narcotic analgesic, acetaminophen (Ofirmev®) or ketorolac (Toradol®), provides better post-operative pain control when combined with an opioid patient-controlled analgesia (PCA) pump. Secondary objectives include comparisons of the rates of ileus, post-operative bleeding, transfusions, and length-of-hospitalization (LOH).
A prospective, randomized trial of acetaminophen (A) 1-g intravenous (IV) every 6-h or ketorolac (K) 15-mg IV every 6-h from post-operative day 1-3 in addition to an opioid PCA for patients undergoing benign or malignant gynecologic laparotomy procedures was performed. Abstracted data included pain levels via visual analogue pain scales (VAS), amount of narcotic used, hepatic enzyme levels, hemoglobin, urine output, blood transfusions, time to return of flatus and LOH.
One-hundred patients were accrued and underwent 55 benign gynecologic laparotomies and 45 cancer-related laparotomies. VAS pain levels (3.3 K, 3.5 A) and morphine PCA use (79.1 oral morphine equivalents [OME] K vs. 84.5 A) were not different, however dilaudid PCA usage was less by K patients (84.4 OME K and 136.8 OME A, p < 0.001). There was a significant hemoglobin change between the two groups (2.6 g K vs. 2 g A, p = 0.015), however blood transfusions were equal (28% K, 22% A, p > 0.05). Return of flatus was 2.7-days for K vs. 3.4-days for A (p = 0.011) and LOH was not different (4.4-days K vs. 5.1-days A, p = 0.094).
Both intravenous ketorolac and acetaminophen provide similar post-operative analgesia through VAS pain scales and total usage of morphine via PCA pumps. Use of ketorolac with dilaudid PCA was associated with less dependence on dilaudid and a quicker return of bowel function than acetaminophen, however length of stay and transfusion rates were not different.
确定在与阿片类药物患者自控镇痛(PCA)泵联合使用时,哪种非麻醉性镇痛药(扑热息痛[Ofirmev®]或酮咯酸[Toradol®])能更好地控制术后疼痛。次要目标包括比较肠梗阻、术后出血、输血和住院时间(LOH)的发生率。
对接受良性或恶性妇科剖腹手术的患者,在术后第 1-3 天,除阿片类 PCA 外,分别给予 1g 扑热息痛(A)静脉推注(IV)每 6 小时或 15mg 酮咯酸(K)IV 每 6 小时,进行前瞻性、随机试验。提取的数据包括视觉模拟疼痛量表(VAS)的疼痛水平、阿片类药物的使用量、肝酶水平、血红蛋白、尿量、输血、肛门排气恢复时间和 LOH。
共入组 100 例患者,其中 55 例接受良性妇科剖腹术,45 例接受癌症相关剖腹术。VAS 疼痛评分(3.3 K,3.5 A)和吗啡 PCA 使用量(79.1 口服吗啡当量[OME] K 与 84.5 A)无差异,但 K 患者的地佐辛 PCA 使用量较少(84.4 OME K 和 136.8 OME A,p < 0.001)。两组血红蛋白均有显著变化(2.6 g K 与 2 g A,p = 0.015),但输血率相等(28% K,22% A,p > 0.05)。K 组肛门排气时间为 2.7 天,A 组为 3.4 天(p = 0.011),LOH 无差异(K 组 4.4 天,A 组 5.1 天,p = 0.094)。
静脉注射酮咯酸和扑热息痛通过 VAS 疼痛量表和 PCA 泵使用的吗啡总量提供相似的术后镇痛效果。与扑热息痛相比,使用酮咯酸联合地佐辛 PCA 与对地佐辛的依赖性降低和更快的肠道功能恢复有关,但住院时间和输血率无差异。